Please enter the email address you used to register, then we will send you a link to choose a new password
https://www.prnewswire.com/news-releases/fda-permits-marketing-of-first-point-of-care-hepatitis-c-rna-test-302185013.html
The Danaher Beacon for Brain Injury Diagnostics seeks to identify mild Traumatic Brain Injury (TBI) earlier and more precisel...
Citigroup analyst Patrick Donnelly maintains Danaher (NYSE:DHR) with a Buy and raises the price target from $280 to $290.
TD Cowen analyst Dan Brennan maintains Danaher (NYSE:DHR) with a Buy and raises the price target from $280 to $290.
B of A Securities analyst Derik De Bruin maintains Danaher (NYSE:DHR) with a Neutral and raises the price target from $258 t...
Barclays analyst Luke Sergott maintains Danaher (NYSE:DHR) with a Equal-Weight and raises the price target from $260 to $270.